Article

Protecting assets is top priority in malpractice climate

Author(s):

Christopher R. Jarvis, MBA,David B. Mandell, JD, MBA

Regardless of the state of the malpractice insurance market, physicians always should view asset protection as an important part of their business and personal financial plan. When we use the term "asset protection," we mean shielding personal and practice assets from all potential lawsuits, including malpractice claims.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) From MIGS to gene therapy: Inder Paul Singh, MD, celebrates the past and future of glaucoma care
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
Related Content
Beacon Therapeutics exercises option to license Abeona Therapeutics’ AAV204 capsid
July 3rd 2025

Beacon Therapeutics exercises option to license Abeona Therapeutics’ AAV204 capsid

3 Things You Should Know About the GA Pipeline
June 4th 2025

3 Things You Should Know About Interventional Glaucoma Comanagement

RetinalGenix Technologies and LabCorp partner on DNA/RNA/GPS Pharmaco-Genetic Mapping platform
July 2nd 2025

RetinalGenix Technologies and LabCorp partner on DNA/RNA/GPS Pharmaco-Genetic Mapping platform

Patient-Centered Treatment Strategies in the Management of nAMD and DME
May 30th 2025

Patient-Centered Treatment Strategies in the Management of nAMD and DME

(Image credit: AdobeStock/Vitalii Vodolazskyi) Yale researchers identify corneal ulcer pathogens by testing tears
July 1st 2025

Yale researchers identify corneal ulcer pathogens by testing tears

Health Canada approves Biocon's Yesafili, biosimilar to Eylea
July 1st 2025

Health Canada approves Biocon's Yesafili, biosimilar to Eylea

© 2025 MJH Life Sciences

All rights reserved.